UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Selection bias for treatments with positive Phase 2 results

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2020-09, Vol.19 (5), p.679-691

2020

Volltextzugriff (PDF)

Discounting phase 2 results when planning phase 3 clinical trials

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2012-09, Vol.11 (5), p.373-385

2012

Volltextzugriff (PDF)

Recent Developments in the Prevention and Treatment of Missing Data

Therapeutic innovation & regulatory science, 2014-01, Vol.48 (1), p.68-80

2014

Volltextzugriff (PDF)

Attrition in Randomized Controlled Clinical Trials: Methodological Issues in Psychopharmacology

Biological psychiatry (1969), 2006-06, Vol.59 (11), p.1001-1005

2006

Volltextzugriff (PDF)

The relationship of blood transfusion, tumor staging, and cancer recurrence

Transfusion (Philadelphia, Pa.), 1990-05, Vol.30 (4), p.291-294

1990

Volltextzugriff (PDF)

The impact and implication of regression to the mean on the design and analysis of medical investigations

Statistical methods in medical research, 1997-02, Vol.6 (2), p.115-128

1997

Volltextzugriff (PDF)

An Approach to Rationalize Partitioning Sample Size into Individual Regions in a Multiregional Trial

Drug information journal, 2008-03, Vol.42 (2), p.139-147

2008

Volltextzugriff (PDF)

Some Issues concerning the Normalization of Laboratory Data Based on Reference Ranges

Drug information journal, 2001, Vol.35 (1), p.153-156

Chuang-Stein, Christy

2001

Volltextzugriff (PDF)

FDA Draft Guidance on Adaptive Design Clinical Trials: Pfizer's Perspective

Journal of biopharmaceutical statistics, 2010-11, Vol.20 (6), p.1143-1149

2010

Volltextzugriff (PDF)

Safety Analysis in Controlled Clinical Trials

Drug information journal, 1998-10, Vol.32 (1_suppl), p.1363S-1372S

Chuang-Stein, Christy

1998

Volltextzugriff (PDF)

Testing for Superiority or Inferiority after Concluding Equivalence?

Drug information journal, 2001, Vol.35 (1), p.141-143

Chuang-Stein, Christy

2001

Volltextzugriff (PDF)

Recent Advancements in the Analysis and Presentation of Safety Data

Drug information journal, 2001, Vol.35 (2), p.377-397

2001

Volltextzugriff (PDF)

Considerations on Endpoint Selection, Weighting Determination, and Uncertainty Evaluation in the Benefit-Risk Assessment of Medical Product

Statistics in biopharmaceutical research, 2016-10, Vol.8 (4), p.417-425

2016

Volltextzugriff (PDF)

Selecting and Integrating Data Sources in Benefit-Risk Assessment: Considerations and Future Directions

Statistics in biopharmaceutical research, 2016-10, Vol.8 (4), p.394-403

2016

Volltextzugriff (PDF)

A log-linear model for ordinal data to characterize differential change among treatments

Statistics in medicine, 1989-05, Vol.8 (5), p.571-582

1989

Volltextzugriff (PDF)

Viewpoints on the FDA Draft Adaptive Designs Guidance from the PhRMA Working Group

Journal of biopharmaceutical statistics, 2010-11, Vol.20 (6), p.1115-1124

2010

Volltextzugriff (PDF)

Laboratory Data in Clinical Trials: A Statistician's Perspective

Controlled clinical trials, 1998-04, Vol.19 (2), p.167-177

Chuang-Stein, Christy

1998

Volltextzugriff (PDF)

A review of tests for detecting a monotone dose-response relationship with ordinal response data

Statistics in medicine, 1997-11, Vol.16 (22), p.2599-2618

1997

Volltextzugriff (PDF)

Summarizing Laboratory Data with Different Reference Ranges in Multi-Center Clinical Trials

Drug information journal, 1992, Vol.26 (1), p.77-84

Chuang-Stein, Christy

1992

Volltextzugriff (PDF)

Investigating Drug-Induced QT and QTc Prolongation in the Clinic: A Review of Statistical Design and Analysis Considerations: Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team

Drug information journal, 2005-07, Vol.39 (3), p.243-265

Patterson, Scott D.

2005

Volltextzugriff (PDF)

Points for Consideration in the Collection and Analysis of Safety Data

Drug information journal, 1995, Vol.29 (1), p.37-44

Chuang-Stein, Christy

1995

Volltextzugriff (PDF)

An Application of the Beta-Binomial Model to Combine and Monitor Medical Event Rates in Clinical Trials

Drug information journal, 1993, Vol.27 (2), p.515-523

Chuang-Stein, Christy

1993

Volltextzugriff (PDF)

Seize the opportunities

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2004-07, Vol.3 (3), p.157-159

Chuang-Stein, Christy

2004

Volltextzugriff (PDF)

A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressant

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2007-01, Vol.6 (1), p.9-22

2007

Volltextzugriff (PDF)

Clinical Equivalence—A Clarification

Drug information journal, 1999, Vol.33 (4), p.1189-1194

Chuang-Stein, Christy

1999

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(45)
Reviews
(1)

Sprache

Englisch
(46)
Japanisch
(7)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Selection bias for treatments with positive Phase 2 results

Discounting phase 2 results when planning phase 3 clinical trials

Recent Developments in the Prevention and Treatment of Missing Data

Attrition in Randomized Controlled Clinical Trials: Methodological Issues in Psychopharmacology

The relationship of blood transfusion, tumor staging, and cancer recurrence

The impact and implication of regression to the mean on the design and analysis of medical investigations

An Approach to Rationalize Partitioning Sample Size into Individual Regions in a Multiregional Trial

Some Issues concerning the Normalization of Laboratory Data Based on Reference Ranges

FDA Draft Guidance on Adaptive Design Clinical Trials: Pfizer's Perspective

Safety Analysis in Controlled Clinical Trials

Testing for Superiority or Inferiority after Concluding Equivalence?

Recent Advancements in the Analysis and Presentation of Safety Data

Considerations on Endpoint Selection, Weighting Determination, and Uncertainty Evaluation in the Benefit-Risk Assessment of Medical Product

Selecting and Integrating Data Sources in Benefit-Risk Assessment: Considerations and Future Directions

A log-linear model for ordinal data to characterize differential change among treatments

Viewpoints on the FDA Draft Adaptive Designs Guidance from the PhRMA Working Group

Laboratory Data in Clinical Trials: A Statistician's Perspective

A review of tests for detecting a monotone dose-response relationship with ordinal response data

Summarizing Laboratory Data with Different Reference Ranges in Multi-Center Clinical Trials

Investigating Drug-Induced QT and QTc Prolongation in the Clinic: A Review of Statistical Design and Analysis Considerations: Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team

Points for Consideration in the Collection and Analysis of Safety Data

An Application of the Beta-Binomial Model to Combine and Monitor Medical Event Rates in Clinical Trials

Seize the opportunities

A case study comparing a randomized withdrawal trial and a double-blind long-term trial for assessing the long-term efficacy of an antidepressant

Clinical Equivalence—A Clarification

Suchergebnisse filtern